Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Four Rutgers Researchers Honored by R&D Council with 2016 Edison Patent Award

11/4/2016

0 Comments

 
New Brunswick, NJ — The Research & Development Council of New Jersey presented its 2016 Edison Patent Award to a Rutgers professor, two former faculty members at the university and a retired research staffer at the council’s annual awards event on November 3.
 
Raphael Mannino and Ruying Lu, former researchers in the Department of Pathology and Laboratory Medicine at the Rutgers New Jersey Medical School, now both at Matinas BioPharma, was honored for a new drug delivery technology they invented.
 
The technology, which is termed “cochleates made with soy phosphatidylserine,” uses a unique lipid-crystal nano-particle to encapsulate existing drugs and other biologically active compounds, which makes them safer, less toxic, orally bioavailable and more tolerable for patients.
 
The technology is being developed and commercialized by Matinas BioPharma of Bedminster Township, which was founded in 2012.
​Joseph Goffreda, a professor in the Department of Plant Biology and Pathology at Rutgers–New Brunswick, also received the Edison Patent Award. One of his former colleagues will share the honor: Anna Voordeckers, a retired research staff member.
 
They developed a patented hybrid peach variety marketed under the name TangOs® that is able to thrive in New Jersey’s sometimes difficult growing conditions, while maintaining the combination of peach attributes attractive to both consumers and commercial producers.
 
“These inventors’ accomplishments are examples of the extremely valuable innovations that have been developed at Rutgers over its 250-year history,” said Christopher J. Molloy, Rutgers senior vice president for research and economic development.
 
“The unique approach to drug delivery invented by Raphael Mannino and Ruying Lu has great promise for improving the efficacy of numerous medications, and ultimately the lives of many patients around the world,” Dr. Molloy said.
 
“The work by Joseph Goffreda and Anna Voordeckers is among the latest in a long line of valuable innovations that Rutgers has shared with New Jersey growers, who are key contributors to our state’s economy,” Dr. Molloy added.
 
Goffreda, who has 26 other patents for apples, apricots, nectarines and peaches, has led the Rutgers tree fruit breeding program since 1989.
 
The R&D Council’s 37th Patent Award Ceremony and Reception will be held at the Liberty Science Center in Jersey City. The center is home to the nation’s largest IMAX Theater, where a short original film will pay tribute to the honored individuals and the patents of the inventors.
 
About Rutgers
 
Rutgers, The State University of New Jersey, is a leading national research university. Established in 1766 and celebrating a milestone 250th anniversary in 2016, it is the eighth oldest higher education institution in the nation.  More than 69,000 students and 22,000 faculty and staff learn, work and serve the public at sites across New Jersey and around the world. Rutgers–New Brunswick is the state’s only public institution in the prestigious Association of American Universities.
 
Rutgers belongs to the Big Ten Academic Alliance, which comprises 14 world-class research universities. It is among the top 20 public U.S. universities for total R&D funding, and over the past two years has seen a 22 percent increase in research grants and sponsored programs, up to $637.9 million in FY2016.
 
The Office of Research and Economic Development is a central point for industry to access Rutgers and offers a website for industry: businessportal.rutgers.edu.
 
About Matinas BioPharma
 
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections.
 
The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable.
 
The Company's lead drug candidate is MAT2203, an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent).
 
The Company has an open Investigational New Drug (IND) application for MAT2501, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections.
 
The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.
 
For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507